Nicorandil administration shows cardioprotective effects in patients with poor TIMI and collateral flow as well as good flow after AMI

Annals of Nuclear Medicine

Volumn 20, Issue 4, 2006, Pages 277-285

  Toyama, Takuji ^a,b   Seki, Ryotaro ^a   Hoshizaki, Hiroshi ^a   Kawaguchi, Ren ^a   Isobe, Naoki ^a   Adachi, Hitoshi ^a   Oshima, Shigeru ^a   Taniguchi, Koichi ^a   Kasama, Shu ^a  

^a GUNMA UNIVERSITY   (Japan)

^b GUNMA PREFECTURAL CARDIOVASCULAR CENTER   (Japan)

Author keywords

AMI; Cardioprotective effect; Nicorandil

Indexed keywords

15 (4 IODOPHENYL) 3 METHYLPENTADECANOIC ACID I 123; ACETYLSALICYLIC ACID; GLYCERYL TRINITRATE; HEPARIN; NICORANDIL; PYROPHOSPHATE TECHNETIUM TC 99M; TETROFOSMIN TC 99M; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; COLLATERAL CIRCULATION; CONTROLLED STUDY; DRUG EFFECT; DYSKINESIA; FATTY ACID METABOLISM; FEMALE; HEART PERFUSION; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESTENOSIS; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BLOOD FLOW VELOCITY; CARDIOTONIC AGENTS; CORONARY CIRCULATION; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; NICORANDIL; PROGNOSIS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33745813131     PISSN: 09147187     EISSN: 09147187     Source Type: Journal    
DOI: 10.1007/BF02984644     Document Type: Article

References (40)

1. Hillis LD, Former S, Braunwald E. Risk stratification before thrombolytic therapy in patients with acute myocardial infarction. J Am Coll Cardiol 1990; 16: 313-315.
2. Gruppo Italiano per lo Studio Della Streptokinesi Nell' Infarcto Micardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; I: 397-401.
3. Ito H, Taniyama T, Iwakura K, Nishikawa N, Masuyama T, Kuzuya T, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 1999; 33: 654-660.
4. Ishii H, Ichimiya S, Kanashiro M, Amano T, Imai K, Murohara T, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation 2005; 112: 1284-1288.
5. Taniyama Y, Ito H, Iwakura K, Masuyama T, Hori M, Takiuchi S, et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997; 30: 1193-1199.
6. Mahaffey KW, Puma JA, Barbagelata A, et al. Does adenosine in conjunction with thrombolysis reduce infarct size? Results from the controlled, randomized AMISTAD trial. Circulation 1997; 96 Suppl I: I-206.
7. Auchampach JA, Cavero I, Gross GJ. Nicorandil attenuates myocardial dysfunction associated with transient ischemia by opening ATP-dependent potassium channels. J Cardiovasc Pharmacol 1992; 20: 765-771.
8. Mizunuma T, Nithipatikom K, Gross GJ. Effects of nicorandil and glyveryl trinitrate on infarct size, adenosine release, and neutrophil infiltration in the dog. Cardiovasc Res 1995; 29: 482-489.
9. Klein HH, Pich S, Lindert-Heimberg S, Shade-Brittinger C, Maisch B, Nebendahl K. Comparative study on the effects of intracoronary nicorandil and nitroglycerin in ischaemic, reperfused porcine hearts. Eur Heart J 1995; 16: 603-609.
10. Chibana T, Nagamine F, Sunagawa R, Oshiro K, Nakada Y, Shimabukuro M, et al. Comparison of acute hemodynamic and coronary vasodilating effects between nicorandil and glyceryl trinitrate. Arzneim-Forsh/Drug Res 1991; 41: 591-594.
11. Treese N, Erbel R, Meyer J. Acute hemodynamic effects of nicorandil in coronary artery disease. J Cardiovasc Pharm 1992; 20: 52-56.
12. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. J Cardiol 1989; 63: 18J-24J.
13. Doring G. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. J Cardiovasc Pharm 1992; 20 suppl 3: S74-S81.
14. Di Somma S, Liguori V, Petitto M, Carotenuto A, Bokor D, de Divitiis O, et al. A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris. Cardiovasc Drugs Ther 1993; 7: 119-123.
15. Swan Study Group. Comparison of the antiischaemic and antianginal effect of nicorandil and amlodipine in patients with symptomatic stable angina pectoris: the SWAN study. J Clin Basic Cardiol 1999; 2: 213-217.
16. Ce M, Jennings RB, Reimer KA. Preconditioning with ischaemia: a delay of lethal cell injury in ischaemic myocardium. Circulation 1986; 74: 1124-1136.
17. Patel DJ, Purcell J, Fox KM. Cardioprotection by opening of the KATP channel in unstable angina. Eur Heart J 1999; 20: 51-57.
18. Tomai F, Crea F, Gaspardone A, Versaci F, Esposito C, Chiariello L, et al. Mechanisms of cardiac pain during coronary angioplasty. J Am Coll Cardiol 1993; 22: 1892-1896.
19. Yellon DF, Alkulaifi AM, Pugsley WB. Preconditioning the human myocardium. Lancet 1993; 342: 276-277.
20. Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Nishioka K, et al. Impact of spontaneous anterograde flow of the infarct artery on left ventricular function in patients with a first anterior wall acute myocardial infarction. Am J Cardiol 2002; 90: 5-9.
21. Brodie BR, Stuckey TD, Hansen C, Muncy D. Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction. Am J Cardiol 2000; 85: 13-18.
22. Blanke H, Cohen M, Karsch KR, Fagerstrom R, Rentrop KP. Prevalence and significance of residual flow to the infarct zone during the acute phase of myocardial infarction. J Am Coll Cardiol 1985; 5: 827-831.
23. Stone GW, Cox D, Garcia E, Brodie BR, Morice MC, Griffin J, et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation 2001; 104: 636-641.
24. Lee CW, Hong MK, Yang HS, Choi SW, Kim JJ, Park SW, et al. Determinants and prognostic implications of terminal QRS complex distortion in patients treated with primary angioplasty for acute myocardial infarction. Am J Cardiol 2001; 88: 210-213.
25. Bruce CJ, Christian TF, Schaer GL, Spaccavento LJ, Jolly MK, O'Connor MK, et al. Determinants of infarct size after thrombolytic treatment in acute myocardial infarction. Am J Cardiol 1999; 83: 1600-1605.
26. Rentrop KP, Feit F, Sherman W, Stecy P, Hosat S, Cohen M, et al. Late thrombolytic therapy preserves left ventricular function in patients with collateralized total coronary occlusion: primary end point findings of the Second Mount Sinai-New York University Reperfusion Trial. J Am Coll Cardiol 1989; 14: 58-64.
27. Fukuzawa S, Ozawa S, Inagaki M, Shimada K, Sugioka J, Tateno K, et al. Nicorandil affords cardioprotection in patients with acute myocardial infarction treated with primary percutaneous transluminal coronary angioplasty: assessment with thallium-201/iodine-123 BMIPP dual SPECT. J Nucl Cardiol 2000; 7: 447-453.
28. Lim SY, Bae EH, Jeong MH, Kang DG, Lee YS, Kim KH, et al. Effect of combined intracoronary adenosine and nicorandil on no-reflow phenomenon during percutaneous coronary intervention. Circ J 2004; 68: 928-932.
29. Kim JH, Jeong MH, Yun KH, Kim KH, Kang DK, Hong SN, et al. Myocardial protective effects of nicorandil during percutaneous coronary intervention in patients with unstable angina. Circ J 2005; 69: 306-310.
30. Germano G, Kiat H, Kavanagh PB, Moriel M, Mazzanti M, Su HT, et al. Automatic quantification of ejection fraction from gated myocardial perfusion SPECT. J Nucl Med 1995; 36: 2138-2147.
31. Schwaiger M, Schelbert HR, Ellison D, Hansen H, Yeatman L, Vinten-Johansen J, et al. Sustained regional abnormalities in cardiac metabolism after transient ischemia in the chronic dog model. J Am Coll Cardiol 1985; 6: 336-347.
32. Saito S, Mizumura T, Takayama T, Marb E. Antiischemic effects of nicorandil during coronary angioplasty in humans. Cardiovasc Pharmacol 1998; 31: 74-79.
33. Matsubara T, Minatoguchi S, Matsuo H, Hayakawa K, Segawa T, Matsuno Y, et al. Three minute, but not one minute, ischemia and nicorandil have a preconditioning effect in patients with coronary artery disease. J Am Coll Cardiol 2000; 35: 345-351.
34. Gross JG, Auchampach JA. Role of ATP dependent potassium channels in myocardial ischaemia. Cardiovasc Res 1992; 26: 1011-1016.
35. Sato T, Sasaki N, O'Rourke B, Marban E. Nicorandil, a potent cardioprotective agent, acts by opening mitochondrial ATP-dependent potassium channels. J Am Coll Cardiol 2000; 35: 514-518.
36. Yao Z, Gross GJ. Effects of the KATP channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs. Circulation 1994; 89: 1769-1775.
37. Grover GJ, Dalonzo AJ, Dzwonczyk S, Parham CS, Darbenzio RB. Preconditioning is not abolished by the delayed rectifier K+ blocker dofetilide. Am J Physiol 1996; 40: H1207-H1214.
38. Sato T, Sasaki N, O'Rourke B, Marban E. Nicorandil, a potent cardioprotective agent, acts by opening mitochondrial ATP-dependent potassium channels. J Am Coll Cardiol 2000; 35: 514-518.
39. Pieper GM, Gross GJ. Anti-free-radical and neutrophil-modulating properties of the nitrovasodilator, nicorandil. Cardiovasc Drugs Ther 1992; 2: 225-232.
40. Akai K, Wang Y, Sato K, Sekiguchi N, Sugimura A, Kumagai T, et al. Vasodilatory effect of nicorandil on coronary arterial microvessels: its dependency on vessel size and the involvement of the ATP-sensitive potassium channels. J Cardiovasc Pharmacol 1995; 26: 541-547.